m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00264)
Target Name Negative growth regulatory protein MyD118 (GADD45B)
Synonyms
Myeloid differentiation primary response protein MyD118; Negative growth regulatory protein MyD118; MYD118
    Click to Show/Hide
Gene Name GADD45B
Chromosomal Location 19p13.3
Family GADD45 family
Function
Involved in the regulation of growth and apoptosis. Mediates activation of stress-responsive MTK1/MEKK4 MAPKKK.
    Click to Show/Hide
Gene ID 4616
Uniprot ID
GA45B_HUMAN
HGNC ID
HGNC:4096
Ensembl Gene ID
ENSG00000099860
KEGG ID
hsa:4616
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
GADD45B can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by FTO
Cell Line HEK293 cell line Homo sapiens
Treatment: FTO knockout HEK293 cells
Control: Wild type HEK293 cells
 GSE79577
Regulation
logFC: 8.04E-01
p-value: 5.27E-05
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Negative growth regulatory protein MyD118 (GADD45B)-mediated m6A modification in Negative growth regulatory protein MyD118 (GADD45B) mRNA drives skeletal muscle differentiation by activating the p38 MAPK pathway, which provides a molecular mechanism for the regulation of myogenesis via RNA methylation.
Target Regulation Up regulation
Responsed Disease Muscular dystrophies ICD-11: 8C70
 Disease Info 
Pathway Response Nucleotide excision repair hsa03420
MAPK signaling pathway hsa04010
Cell Process DNA repair
In-vitro Model GPM (Goat primary myoblasts)
In-vivo Model Sixteen female goats in good body condition and suitable for pregnancy were selected. All selected goats underwent estrus synchronization treatment and were naturally mated. After 75 days of gestation, four male fetuses were removed from five pregnant goats during abortion operations, and their longissimus muscle samples were collected.
Protein virilizer homolog (VIRMA) [WRITER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary VIRMA has an oncogenic role in germ cell tumor confirming our previous tissue-based study and is further involved in response to cisplatin by interfering with DNA repair. Enhanced response to cisplatin after VIRMA knockdown was related to significant increase in DNA damage (with higher Gamma-H2AX and Negative growth regulatory protein MyD118 (GADD45B) levels) and downregulation of XLF and MRE11.
Target Regulation Down regulation
Responsed Disease Germ cell tumour of testis ICD-11: 2C80.2
 Disease Info 
Responsed Drug Cisplatin Approved
 Drug Info 
In-vitro Model 2102EP Embryonal carcinoma Homo sapiens CVCL_C522
NCC-IT Testicular embryonal carcinoma Homo sapiens CVCL_1451
NT2 Malignant neoplasms Mus musculus CVCL_JA57
TCam-2 Testicular seminoma Homo sapiens CVCL_T012
Testicular cancer [ICD-11: 2C80]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [2]
Response Summary VIRMA has an oncogenic role in germ cell tumor confirming our previous tissue-based study and is further involved in response to cisplatin by interfering with DNA repair. Enhanced response to cisplatin after VIRMA knockdown was related to significant increase in DNA damage (with higher Gamma-H2AX and Negative growth regulatory protein MyD118 (GADD45B) levels) and downregulation of XLF and MRE11.
Responsed Disease Germ cell tumour of testis [ICD-11: 2C80.2]
Target Regulator Protein virilizer homolog (VIRMA) WRITER
 Regulator Info 
Target Regulation Down regulation
Responsed Drug Cisplatin Approved
 Drug Info 
In-vitro Model 2102EP Embryonal carcinoma Homo sapiens CVCL_C522
NCC-IT Testicular embryonal carcinoma Homo sapiens CVCL_1451
NT2 Malignant neoplasms Mus musculus CVCL_JA57
TCam-2 Testicular seminoma Homo sapiens CVCL_T012
Muscular dystrophies [ICD-11: 8C70]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary Negative growth regulatory protein MyD118 (GADD45B)-mediated m6A modification in Negative growth regulatory protein MyD118 (GADD45B) mRNA drives skeletal muscle differentiation by activating the p38 MAPK pathway, which provides a molecular mechanism for the regulation of myogenesis via RNA methylation.
Responsed Disease Muscular dystrophies [ICD-11: 8C70]
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Nucleotide excision repair hsa03420
MAPK signaling pathway hsa04010
Cell Process DNA repair
In-vitro Model GPM (Goat primary myoblasts)
In-vivo Model Sixteen female goats in good body condition and suitable for pregnancy were selected. All selected goats underwent estrus synchronization treatment and were naturally mated. After 75 days of gestation, four male fetuses were removed from five pregnant goats during abortion operations, and their longissimus muscle samples were collected.
Cisplatin [Approved]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [2]
Response Summary VIRMA has an oncogenic role in germ cell tumor confirming our previous tissue-based study and is further involved in response to cisplatin by interfering with DNA repair. Enhanced response to cisplatin after VIRMA knockdown was related to significant increase in DNA damage (with higher Gamma-H2AX and Negative growth regulatory protein MyD118 (GADD45B) levels) and downregulation of XLF and MRE11.
Target Regulator Protein virilizer homolog (VIRMA) WRITER
 Regulator Info 
Target Regulation Down regulation
Responsed Disease Germ cell tumour of testis ICD-11: 2C80.2
 Disease Info 
In-vitro Model 2102EP Embryonal carcinoma Homo sapiens CVCL_C522
NCC-IT Testicular embryonal carcinoma Homo sapiens CVCL_1451
NT2 Malignant neoplasms Mus musculus CVCL_JA57
TCam-2 Testicular seminoma Homo sapiens CVCL_T012
References
Ref 1 FTO-mediated demethylation of GADD45B promotes myogenesis through the activation of p38 MAPK pathway. Mol Ther Nucleic Acids. 2021 Jun 24;26:34-48. doi: 10.1016/j.omtn.2021.06.013. eCollection 2021 Dec 3.
Ref 2 The component of the m(6)A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. J Exp Clin Cancer Res. 2021 Aug 25;40(1):268. doi: 10.1186/s13046-021-02072-9.